oral glp 1 for weight loss With FDA approval of Wegovy pill, new era of GLP-1 drugs begins Feel fuller Novel oral GLP-1 receptor agonist
Description
February 1, 2025
Approval for Cardiovascular Risk Reduction Ongoing cardiovascular outcomes trials (CVOT) studies clearly demonstrated that three of the diabetes incretin medications (liraglutide, dulaglutide and semaglutide) and one of the weight loss versions of this class (Wegovy) also reduce cardiovascular disease risk
Learn how you can determine the best treatment for you
View the LIV Body GLP-1 program - see current offer and eligibility details (official LIV Body page) How to Read LIV Body's Marketing Language LIV Body runs active advertising
